Cancer detection specialist Imagion Biosystems Limited (ASX: IBX) has announced that Monash Health has been established as the first clinical site and is ready to commence enrollment of patients for the MagSense HER2 breast cancer Phase I first-in-human study.
Dr Jane Fox, the current Director of Breast Services at Monash Health, which encompasses breast surgery and the Monash BreastScreen program, has been named as the Principal Investigator of the MagSense study. Dr Fox is also a senior lecturer in the Monash University Department of Surgery and a senior leader of the multi-disciplinary team at the Monash Cancer Centre which includes medical imaging, medical oncology and radiation oncology.
We are delighted to be working with a leading healthcare organisation and with Dr. Jane Fox, a highly regarded clinician who has dedicated her career to improving outcomes for patients with breast cancer and who is strongly supportive of the trial. After all the diligence and hard work, it is extremely exciting to be initiating our first clinical study,” said Bob Proulx, Executive Chairman of Imagion Biosystems.
Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology, the company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible.
A new functional imaging method that holds the promise of being more sensitive and safer for detecting cancers and other critical diseases. Designated by the US FDA as a “Breakthrough Device”, MagSense technology will help transform cancer care.
MagSense technology does not use ionising radiation, radioactive tracers, or strong magnetic fields. And unlike existing imaging methods that can only identify a “region of interest” and cannot differentiate benign tumours from malignant cancer, MagSense nanoparticles are designed to be detectable only when attached to cancer cells.
